Key result
Multidisciplinary interventions targeting early metabolic comorbidities, such as obesity, diabetes, and cardiovascular disease, offer potential strategies to curb the progression of MASLD and related hepatocellular carcinoma.
Why the study?
NAFLD-related HCC incidence is increasing, patients are often diagnosed late with poor prognosis, and corresponding multidisciplinary intervention measures targeting early metabolic comorbidities remain needed.
This review highlights the importance of early multidisciplinary management of metabolic comorbidities to curb the progression of MASLD and related hepatocellular carcinoma.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for multidisciplinary metabolic care in MASLD; randomized trials needed before practice change.
In recent years, non-alcoholic fatty liver disease (NAFLD) has developed rapidly worldwide and has become the main cause of chronic liver disease. With the increase in prevalence, the incidence of NAFLD-related hepatocellular carcinoma (HCC) has increased sharply. These patients are often diagnosed late, have a poor prognosis, and there is still a lack of corresponding intervention measures. The close connection between NAFLD and metabolic comorbidities has given rise to a new name, “Metabolic dysfunction-associated steatotic liver disease” (MASLD), which provides us with new intervention ideas to curb the progression of liver disease through the common intrinsic mechanisms related to regulating metabolic conditions through multidisciplinary combined treatment of early metabolic comorbidities. This review analyzes the clinical status of NAFLD/MASLD and the intrinsic relationship with related metabolic syndrome, explores the potentially beneficial interventions for MASLD and related HCC in multidisciplinary treatment, including some commonly used clinical drugs, deepens the understanding of the disease and provides references for prevention and intervention.
No takes yet. Share an insight, caveat, or question.
Chao Xu (2024) conducted a review in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and related Hepatocellular Carcinoma (HCC). Multidisciplinary interventions (lifestyle modifications and pharmacological treatments for comorbidities) was evaluated. Multidisciplinary interventions targeting early metabolic comorbidities, such as obesity, diabetes, and cardiovascular disease, offer potential strategies to curb the progression of MASLD and related hepatocellular carcinoma.
Synapse has enriched 10 related papers. Consider them for comparative context: